News & Events
Latest News
Aravax Appoints Dr Adrian Parry as Director of CMC as it Continues to Build Phase 3 Development Capabilities
23 June 2025/by axergyAravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
2 June 2025/by axergyAravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
21 January 2025/by axergyAravax Establishes Pharmaceutical Development base on the Oxford Science Park with a Focus on Developing Manufacturing Capabilities in the UK
14 November 2024/by axergyAravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
28 October 2024/by axergyAravax Appoints Dr Paul Laidler as VP Pharmaceutical Development
1 May 2024/by axergyAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
23 January 2024/by axergyAravax appoints Annette Leahy as Director of Clinical Operations
21 July 2023/by axergyAravax doses first patient in Phase 2 peanut allergy clinical trials
1 June 2023/by axergyAravax initiates Phase 2 peanut allergy clinical trials in Australia
8 March 2023/by axergyAravax commences Phase 2 in peanut allergy with $20m Series B from Brandon Capital and Tenmile
20 December 2022/by axergyAravax appoints Dr Brett Haumann to Board of Directors
6 May 2022/by axergy© Aravax
Contact Us
Email: info@aravax.com.au
Australia
Level 9, 31 Queen St, Melbourne, Victoria, 3000 Australia
Tel: +61 (0)3 9657 0700
UK
John Eccles House, Oxford Science Park
Oxford, OX4 4GP, United Kingdom
